Market Closed -
Nasdaq
04:00:00 2024-06-07 pm EDT
|
5-day change
|
1st Jan Change
|
30.77
USD
|
+0.69%
|
|
+1.32%
|
+6.54%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
523.1
|
1,044
|
1,751
|
1,031
|
1,437
|
1,541
|
-
|
-
|
Enterprise Value (EV)
1 |
523.1
|
1,044
|
1,751
|
683
|
732.2
|
988.3
|
1,014
|
1,024
|
P/E ratio
|
-6.38
x
|
-22.8
x
|
-17.7
x
|
-17.3
x
|
-8.04
x
|
-7.7
x
|
-7.13
x
|
-6.74
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
30.8
x
|
23.2
x
|
88.5
x
|
14.6
x
|
2,757
x
|
7,707
x
|
2,055
x
|
1,798
x
|
EV / Revenue
|
30.8
x
|
23.2
x
|
88.5
x
|
9.65
x
|
1,405
x
|
4,941
x
|
1,352
x
|
1,194
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-4.12
x
|
-4.31
x
|
-3.72
x
|
-3.26
x
|
EV / FCF
|
-
|
-22.4
x
|
-
|
-6.74
x
|
-6.45
x
|
-5.71
x
|
-5.31
x
|
-5.04
x
|
FCF Yield
|
-
|
-4.46%
|
-
|
-14.8%
|
-15.5%
|
-17.5%
|
-18.8%
|
-19.8%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
30,484
|
31,125
|
36,962
|
38,553
|
49,743
|
50,094
|
-
|
-
|
Reference price
2 |
17.16
|
33.55
|
47.38
|
26.75
|
28.88
|
30.77
|
30.77
|
30.77
|
Announcement Date
|
2/27/20
|
3/1/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
16.98
|
44.94
|
19.79
|
70.81
|
0.521
|
0.2
|
0.75
|
0.8571
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-177.6
|
-229.2
|
-272.6
|
-314.3
|
EBIT
1 |
-46.99
|
-47.18
|
-95.81
|
-63.4
|
-178.7
|
-227.6
|
-250.1
|
-273.3
|
Operating Margin
|
-276.77%
|
-104.97%
|
-484.02%
|
-89.53%
|
-34,296.74%
|
-113,807.29%
|
-33,352.96%
|
-31,884.57%
|
Earnings before Tax (EBT)
1 |
-42.42
|
-45.57
|
-95.54
|
-58.97
|
-151.7
|
-202.7
|
-230.6
|
-249.4
|
Net income
1 |
-43.33
|
-45
|
-95.54
|
-59.04
|
-152.1
|
-199
|
-228.8
|
-250.1
|
Net margin
|
-255.22%
|
-100.12%
|
-482.68%
|
-83.38%
|
-29,192.9%
|
-99,514.56%
|
-30,505.09%
|
-29,175.16%
|
EPS
2 |
-2.690
|
-1.470
|
-2.670
|
-1.550
|
-3.590
|
-3.995
|
-4.315
|
-4.564
|
Free Cash Flow
1 |
-
|
-46.53
|
-
|
-101.3
|
-113.6
|
-173
|
-191
|
-203
|
FCF margin
|
-
|
-103.54%
|
-
|
-143.12%
|
-21,795.2%
|
-86,500%
|
-25,466.67%
|
-23,683.41%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/27/20
|
3/1/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
9.556
|
2.382
|
60.24
|
2.055
|
6.135
|
0.521
|
-
|
-
|
-
|
-
|
-
|
0.0556
|
0.1667
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-49.15
|
-53.32
|
-55.43
|
-58.94
|
-62.68
|
EBIT
1 |
-21.55
|
-31.67
|
26.35
|
-31.49
|
-26.58
|
-39.2
|
-45.3
|
-44.75
|
-49.43
|
-53.6
|
-55.51
|
-58.31
|
-60.29
|
Operating Margin
|
-225.47%
|
-1,329.64%
|
43.74%
|
-1,532.51%
|
-433.27%
|
-7,524.95%
|
-
|
-
|
-
|
-
|
-
|
-104,946.83%
|
-36,170.43%
|
Earnings before Tax (EBT)
1 |
-21.4
|
-31.48
|
26.84
|
-29.99
|
-24.34
|
-36.1
|
-38.88
|
-36.13
|
-40.61
|
-45.21
|
-50.92
|
-53.1
|
-56.52
|
Net income
1 |
-21.4
|
-31.48
|
26.84
|
-30.02
|
-24.38
|
-36.14
|
-39.01
|
-36.21
|
-40.74
|
-45.29
|
-49.74
|
-51.59
|
-54.42
|
Net margin
|
-223.96%
|
-1,321.75%
|
44.56%
|
-1,460.88%
|
-397.34%
|
-6,935.7%
|
-
|
-
|
-
|
-
|
-
|
-92,847.75%
|
-32,653.4%
|
EPS
2 |
-0.5800
|
-0.8500
|
0.6800
|
-0.7800
|
-0.6400
|
-0.9000
|
-0.9200
|
-0.7300
|
-0.9400
|
-0.9100
|
-0.9752
|
-1.002
|
-1.059
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/22
|
5/4/22
|
8/3/22
|
11/2/22
|
2/23/23
|
4/25/23
|
8/3/23
|
11/3/23
|
2/22/24
|
4/25/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
348
|
704
|
553
|
527
|
518
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-46.5
|
-
|
-101
|
-114
|
-173
|
-191
|
-203
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-29.1%
|
-31.9%
|
-54.7%
|
-122%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.54
|
1.02
|
0.37
|
1.24
|
1
|
1.25
|
1
|
Capex / Sales
|
-
|
1.21%
|
5.15%
|
0.52%
|
238.2%
|
500%
|
166.67%
|
116.67%
|
Announcement Date
|
2/27/20
|
3/1/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Last Close Price
30.77
USD Average target price
56
USD Spread / Average Target +82.00% Consensus |
1st Jan change
|
Capi.
|
---|
| +6.54% | 1.54B | | +51.85% | 57.87B | | +40.23% | 40.25B | | -5.25% | 39.94B | | -5.16% | 28.54B | | +12.79% | 26.4B | | -20.18% | 19.33B | | +30.88% | 12.4B | | +0.61% | 12.23B | | +25.06% | 12.2B |
Other Biotechnology & Medical Research
|